Amino acid infusion versus placebo to determine if renal outcomes are improved after pulmonary organ transplantation
The impact of Amino acid Infusion on Renal outcomes after Pulmonary Organ Transplantation
Alfred Health
50 participants
Feb 2, 2026
Interventional
Conditions
Summary
Acute kidney injury (AKI) occurs in up to two-thirds of patients after lung transplantation, and renal replacement therapy is required in 10%. Amino acid infusion has been shown to reduce AKI in cardiac surgical patients. No trial of amino acid infusion has taken place in lung transplant. The AIRPORT study will determine feasibility of a larger definitive trial and investigate efficacy using markers of kidney function.
Eligibility
Inclusion Criteria1
- All adult patients undergoing lung transplantation
Exclusion Criteria5
- Current or planned dialysis
- Combined lung and kidney transplant, or combined lung and liver transplant
- Prior kidney transplant
- Known allergy to one of the amino acids
- Congenital abnormality of amino acid metabolism
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Balanced amino acid infusion (Synthamin 17 10%) started after induction of anaesthesia and administered by the clinician and continued for 72 hours, until start of renal replacement therapy, or discharge from ICU (whichever comes first). Dose will be 2g/kg ideal body weight/day (to a maximum dose 100g/day). Ideal body weight will be determined with the Devine formula. Intervention will be confirmed on electronic medical record and by research administration staff.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12625001381471